Case report: Approaches to treatment-refractory and super-refractory glutamic acid decarboxylase antibody-spectrum
Ravi Rajmohan1, Shivali Baveja2, Dai Nguyen3
1Department of Neurology, University of California, Irvine, CA, United States.
Background:
Glutamic acid decarboxylase antibody-spectrum disorders (GAD-SDs) include a group of autoimmune neurological diseases associated with neuronal excitability, most noticeably stiff person syndrome. Immune modulators are the mainstay of treatment, but a significant number of patients remain refractory.
Methods:
We present our single-center experience of eight cases of GAD-SD, two of which were refractory to immune modulatory treatments.
Results:
Of the two cases that were refractory to immunomodulation, one showed significant improvement with bilateral globus pallidus interna deep brain stimulation (GPi DBS) placement, and the other showed significant improvement with autologous hematopoietic stem cell transplant (aHSCT).
Discussion:
To our knowledge, this is the first instance of GPi DBS placement being noted to improve GAD-SD movements.
More Related Videos
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
10:16In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Related Concept Videos
Antiepileptic Drugs: Glutamate Antagonists
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Psychosis: Goals of Pharmacotherapy
Alzheimer's Disease: Treatment
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Drug Therapy
Antianxiety Medications
